TMSDRDSI: Drug Design MSc

TMSDRDSING01: MSc Drug Design
WIBRG001, WIBRG002, WIBRG003, WIBRG004, 5 + 6

View Online

1

Wilhelm S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews Drug Discovery 2006;**5**:835–44. doi:10.1038/nrd2130

2

Smith RA. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. Bioorganic & Medicinal Chemistry Letters 2001;**11**:2775–8. doi:10.1016/S0960-894X(01)00571-6

3

Kola I, Landis J. Opinion: Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery 2004;**3**:711–6. doi:10.1038/nrd1470

4

Swinney DC, Anthony J. How were new medicines discovered? Nature Reviews Drug Discovery 2011;**10**:507–19. doi:10.1038/nrd3480

5

Macarron R, Banks MN, Bojanic D, et al. Impact of high-throughput screening in biomedical research. Nature Reviews Drug Discovery 2011;**10**:188–95. doi:10.1038/nrd3368

6

Selzer, P. M., Rohwer, A., Marhöfer, R. J. Applied bioinformatics: an introduction. Berlin: : Springer 2008.

7

Xiong, Jin. Essential bioinformatics. New York: : Cambridge University Press 2006.

8

Orengo, Christine Ann, Thornton, Janet M., Jones, David Tudor. Bioinformatics: genes, proteins and computers. Oxford: : BIOS 2003. http://www.vlebooks.com/vleweb/product/openreader?id=UCL&isbn=9780203427828

9

Zvelebil, Marketa J., Baum, Jeremy O. Understanding bioinformatics. London: : Garland Science 2008. https://bibliu.com/app/#/view/books/9781136976964/pdf2htmlex/index.html#page_Cover

10

Gu, Jenny, Bourne, Philip E. Structural bioinformatics. 2nd ed. Hoboken, N.J.: : Wiley 2008.

11

Petsko, Gregory A., Ringe, Dagmar. Protein structure and function. London: : New Science 2004.

12

Nelson, David L., Cox, Michael M., Lehninger, Albert L. Lehninger principles of biochemistry . 5th ed. Basingstoke: : W.H. Freeman 2008.

13

Chandra N. Computational systems approach for drug target discovery. Expert Opinion on Drug Discovery 2009;**4**:1221–36. doi:10.1517/17460440903380422

14

Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nature Reviews Drug Discovery 2006;**5**:993–6. doi:10.1038/nrd2199

15

Fitt R, Nodder E. Setting the threshold for industrial application: the UK diverges from Europe. Journal of Intellectual Property Law & Practice 2010;**5**:560–5. doi:10.1093/jiplp/jpq061

16

Ikura M, Inouye M. NMR structure of the histidine kinase domain of the : E. coli: osmosensor EnvZ : Article : Nature. Nature 1998;**396**:88–92. doi:10.1038/23968

17

Krohn KA, Link JM. Interpreting enzyme and receptor kinetics: keeping it simple, but not too simple. Nuclear Medicine and Biology 2003;**30**:819–26. doi:10.1016/S0969-8051(03)00132-X

18

Jarnagin K. Receptor Binding in Drug Discovery. In: eLS.

19

Jarnagin K. Receptor Binding in Drug Discovery. Chichester: : John Wiley & Sons, Ltd 2001. doi:10.1038/npg.els.0000056

20

Cornish-Bowden, Athel. Fundamentals of enzyme kinetics. 3rd ed. London: : Portland 2004.

21

Copeland, Robert Allen. Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists. Hoboken, N.J.: : J. Wiley 2005. https://onlinelibrary.wiley.com/doi/book/10.1002/9781118540398

22

Gibb, Alasdair J., Foreman, John C., Johansen, Torben. Textbook of receptor pharmacology. 3rd ed. Boca Raton, FL: : CRC Press 2011.

23

Rang, H. P., Dale, M. Maureen. Pharmacology. 9th ed. Edinburgh: : Churchill Livingstone 2019. https://elsevierelibrary.co.uk/product/9780702074462

24

Colquhoun D. Binding, gating, affinity and efficacy: The interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. British Journal of Pharmacology 1998;**125**:923–47. doi:10.1038/sj.bjp.0702164

25

Khawaja X, Dunlop J, Kowal D. Scintillation proximity assay in lead discovery. Expert Opinion on Drug Discovery 2008;**3**:1267–80. doi:10.1517/17460441.3.11.1267

26

Kenakin TP. Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nature Reviews Drug Discovery 2009;**8**:617–26. doi:10.1038/nrd2838

27

Dunlop J. High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nature Reviews Drug Discovery 2008;**7**:358–68. doi:10.1038/nrd2552

28

Hopkins AL, Groom CR. Opinion: The druggable genome. Nature Reviews Drug Discovery 2002;**1**:727–30. doi:10.1038/nrd892

29

Richard M. Durbin. A map of human genome variation from population-scale sequencing. Nature 2010;**467**:1061–73. doi:10.1038/nature09534

30

Thomas, Gareth. Fundamentals of medicinal chemistry. 2003.

31

Patrick, Graham L. An introduction to medicinal chemistry. 2017.

32

Leach, Andrew R., Gillet, Valerie J. An introduction to chemoinformatics. 2003.

33

Engel, Thomas, Gasteiger, J. Chemoinformatics: a textbook. 2003.

34

Gasteiger, J. Handbook of chemoinformatics: from data to knowledge. 2003. https://onlinelibrary.wiley.com/doi/book/10.1002/9783527618279

35

Bissantz C, Kuhn B, Stahl M. A Medicinal Chemist's Guide to Molecular Interactions. Journal of Medicinal Chemistry 2010;**53**:5061–84. doi:10.1021/jm100112j

36

Matter H. Selecting Optimally Diverse Compounds from Structure Databases: A Validation Study of Two-Dimensional and Three-Dimensional Molecular Descriptors. Journal of Medicinal Chemistry 1997;**40**:1219–29. doi:10.1021/jm960352+

37

Willett P, Barnard JM, Downs GM. Chemical Similarity Searching. Journal of Chemical Information and Modeling 1998;**38**:983–96. doi:10.1021/ci9800211

38

Welsch ME, Snyder SA, Stockwell BR. Privileged scaffolds for library design and drug discovery. Current Opinion in Chemical Biology 2010;**14**:347–61. doi:10.1016/j.cbpa.2010.02.018

39

Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 1997;**23**:3–25. doi:10.1016/S0169-409X(96)00423-1

40

Veber DF, Johnson SR, Cheng H-Y, et al. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. Journal of Medicinal Chemistry 2002;**45**:2615–23. doi:10.1021/jm020017n

41

Blake JF. Identification and Evaluation of Molecular Properties Related to Preclinical Optimization and Clinical Fate. Medicinal Chemistry 2005;**1**:649–55. doi:10.2174/157340605774598081

42

Beck A, Wurch T, Bailly C, et al. Strategies and challenges for the next generation of

therapeutic antibodies. Nature Reviews Immunology 2010;**10**:345–52. doi:10.1038/nri2747

43

Bradbury ARM, Sidhu S, Dübel S, et al. Beyond natural antibodies: the power of in vitro display technologies. Nature Biotechnology 2011;**29**:245–54. doi:10.1038/nbt.1791

44

Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Experimental Cell Research 2011;**317**:1255–60. doi:10.1016/j.yexcr.2011.03.010

45

Pillay V, Gan HK, Scott AM. Antibodies in oncology. New Biotechnology 2011;**28**:518–29. doi:10.1016/j.nbt.2011.03.021

46

Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nature Reviews Drug Discovery 2006;**5**:147–59. doi:10.1038/nrd1957

47

Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology 2010;**10**:317–27. doi:10.1038/nri2744

48

Ducry L, Stump B. Antibody−drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. Bioconjugate chemistry 2010;**21**:5–13. doi:10.1021/bc9002019

49

Alley SC, Okeley NM, Senter PD. Antibody–drug conjugates: targeted drug delivery for cancer. Current Opinion in Chemical Biology 2010;**14**:529–37.

doi:10.1016/j.cbpa.2010.06.170

50

Webb S. Pharma interest surges in antibody drug conjugates. Nature Biotechnology 2011; **29**:297–8. doi:10.1038/nbt0411-297

51

Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nature Biotechnology 2005;**23**:1126–36. doi:10.1038/nbt1142

52

Jinek M, Doudna JA. A three-dimensional view of the molecular machinery of RNA interference. Nature 2009;**457**:405–12. doi:10.1038/nature07755

53

Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009;**457**:426–33. doi:10.1038/nature07758

54

Grimm D. Small silencing RNAs: State-of-the-art. Advanced Drug Delivery Reviews 2009;**61**:672–703. doi:10.1016/j.addr.2009.05.002

55

Vaishnaw AK, Gollob J, Gamba-Vitalo C, et al. A status report on RNAi therapeutics. Silence 2010;**1**. doi:10.1186/1758-907X-1-14

56

Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Therapy 2005;**13**:225–34. doi:10.1038/sj.gt.3302641

57

Kalluri R, Kanasaki K. RNA interference: Generic block on angiogenesis. Nature 2008;**452**:543–5. doi:10.1038/452543a

58

Human embryonic stem cells: Derivation, culture, and differentiation: A review.

59

Stadtfeld M, Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes & Development 2010;**24**:2239–63. doi:10.1101/gad.1963910

60

Watt FM, Driskell RR. The therapeutic potential of stem cells. Philosophical Transactions of the Royal Society B: Biological Sciences 2010;**365**:155–63. doi:10.1098/rstb.2009.0149

61

Brignier AC, Gewirtz AM. Embryonic and adult stem cell therapy. Journal of Allergy and Clinical Immunology 2010;**125**:S336–44. doi:10.1016/j.jaci.2009.09.032

62

Lledo P-M, Merkle FT, Alvarez-Buylla A. Origin and function of olfactory bulb interneuron diversity. Trends in Neurosciences 2008;**31**:392–400. doi:10.1016/j.tins.2008.05.006

63

Murray CW. Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency. Journal of Medicinal Chemistry 2010;**53**:5942–55. doi:10.1021/jm100059d

64

Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug

Discovery Today 2004;**9**:430–1. doi:10.1016/S1359-6446(04)03069-7

65

Congreve M, Chessari G, Tisi D, et al. Recent Developments in Fragment-Based Drug Discovery. Journal of Medicinal Chemistry 2008;**51**:3661–80. doi:10.1021/jm8000373

66

Murray CW, Rees DC. The rise of fragment-based drug discovery. Nature Chemistry 2009;**1**:187–92. doi:10.1038/nchem.217

67

Baurin N, Aboul-Ela F, Barril X, et al. Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets. Journal of Chemical Information and Modeling 2004;**44**:2157–66. doi:10.1021/ci049806z

68

Woodhead AJ. Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design. Journal of Medicinal Chemistry 2010;**53**:5956–69. doi:10.1021/jm100060b

69

DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. Journal of Health Economics 2003;**22**:151–85. doi:10.1016/S0167-6296(02)00126-1